Piribo: Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market”. http://www.piribo.com/publications/finance_investment/financial_markets_research_spectrum_pharmaceuticals_oral_satraplatin.html

There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.

Highlights
Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.

Scope
- Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
- Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option
Reasons to Purchase
- Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
- Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin

Contents
Summary
Company Background
Hormone Refractory Prostate Cancer
Factors Affecting The Potential For Satraplatin
Satraplatin Forecast
Appendix

“Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_spectrum_pharmaceuticals_oral_satraplatin.html

Piribo Product ID: DAT551

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.